Accretion Nutraveda Limited has announced that Unicorn Fund has crossed the 5% shareholding threshold by acquiring 477000 equity shares, representing 6.5883% of the company's total paid-up equity share capital. The disclosure was made on February 17, 2026, pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Acquisition Details

The acquisition represents a significant milestone as Unicorn Fund had no prior holdings in Accretion Nutraveda Limited before this transaction. The fund's shareholding increased from zero to 6.5883% through this acquisition, thereby triggering mandatory disclosure requirements under SEBI regulations.

Mode of Acquisition

Unicorn Fund acquired the equity shares through multiple channels over a two-day period in February 2026:

• IPO Participation: 471000 shares through public issue
  • 466000 shares via Anchor Application on February 4, 2026
  • 5000 shares through QIB Ex Anchor on February 4, 2026
• Secondary Market Purchases: 6000 shares
  • 1000 shares on February 4, 2026
  • 5000 shares on February 5, 2026

Regulatory Compliance

The company received the revised disclosure from Unicorn Fund via email on February 16, 2026, and subsequently filed the mandatory disclosure with BSE Limited. Unicorn Fund does not belong to the promoter or promoter group of Accretion Nutraveda Limited, classifying this as an external investor acquisition.

The acquisition demonstrates investor confidence in Accretion Nutraveda Limited, with Unicorn Fund making a substantial investment through both primary and secondary market channels. The company has fulfilled all regulatory disclosure requirements and informed BSE Limited of this significant shareholding change.

Accretion Nutraveda Limited has announced that Unicorn Fund has acquired a significant stake in the company, crossing the regulatory disclosure threshold of 5%. The acquisition represents a notable investment by the fund in the nutrition and wellness sector company.

Acquisition Details

Unicorn Fund acquired 478000 equity shares of Accretion Nutraveda Limited, representing 6.6022% of the company's total paid-up equity share capital. This acquisition marks the fund's entry into the company as a substantial shareholder, having held no previous stake in the organization.

Transaction Structure and Timeline

The acquisition was executed through multiple channels over two days in February 2026. The fund participated in the company's Initial Public Offering (IPO) while also making strategic purchases from the secondary market.

Acquisition Breakdown:

• IPO Participation: 471000 shares
  • Anchor allocation: 466000 shares on February 4, 2026
  • QIB Ex Anchor: 5000 shares on February 4, 2026
• Secondary Market Purchases: 7000 shares
  • February 4, 2026: 1000 shares
  • February 5, 2026: 6000 shares

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Under these regulations, any acquisition that results in holding 5% or more of a company's equity shares requires mandatory disclosure to stock exchanges.

Fund Authorization

The acquisition was authorized by Mr. Viren S Patel, serving as Designated Partner and Investment Manager for Unicorn Fund. The formal disclosure documentation was completed and submitted to BSE Limited on February 5, 2026, ensuring compliance with regulatory timelines.

Accretion Nutraveda Limited, formerly known as Accretion Nutraveda Private Limited, operates in the nutrition and wellness sector. The company's shares are listed on BSE Limited under scrip code 544694. This acquisition represents Unicorn Fund's confidence in the company's growth prospects and market position within the nutraceutical industry.